In 2016/17, the influenza season in Europe was characterised by an early start (week 46, 2016) and a predominance of A(H3N2) viruses. Overall, 89% of strains reported to the European Centre for Disease Prevention and Control (ECDC) were A(H3N2) viruses \[[@r1]\]. High hospitalisation rates and case fatality ratios were reported among persons aged 65 years and above \[[@r2]\]. The I-MOVE + (Integrated Monitoring of Vaccines in Europe plus) hospital network early estimates, suggested a low 2016/17 seasonal influenza vaccine effectiveness (IVE) against hospitalisation with influenza A(H3N2) among persons aged 65 years and above in the European Union (EU) \[[@r3]\].

Since the A(H3N2) vaccine component has not changed in 2017/18, we present the final 2016/17 season IVE against hospitalisation with influenza A(H3N2) among persons aged 65 years and above in Europe, to inform on the level of IVE that can be expected against A(H3N2) in the upcoming 2017/18 season.

Study design
============

We conducted a multicentre hospital-based test-negative design (TND) case-control study in 27 hospitals from 10 countries (Croatia, Finland, France, Hungary, Italy, Lithuania, the Netherlands, Portugal, Romania and Spain) according to a generic protocol adapted to each local setting \[[@r4]\]. The detailed methods are described elsewhere \[[@r5]\]. In brief, hospital teams identified and swabbed patients aged 65 years and above, hospitalised with signs compatible with a severe acute respiratory infection (SARI) defined as at least one systemic and one respiratory sign or symptom. Swabs were tested with reverse-transcriptase polymerase chain reaction (RT-PCR) for influenza A(H3N2), A(H1N1)pdm09 and B. We compared the odds of vaccination between patients positive for influenza A(H3N2) virus and those negative for any influenza virus. We calculated IVE as (1-odds ratio (OR)).

We measured IVE stratified by age group (65--79 year-olds and ≥ 80 year-olds), presence of underlying conditions (diabetes mellitus, cancer, heart or lung disease, and presence of at least two underlying chronic diseases) and 2015/16 seasonal influenza vaccination status. In a one-stage approach, using logistic regression with the study site as a fixed effect, we adjusted IVE estimates for date of symptoms onset, age (as cubic splines) and individual underlying conditions. Using patients unvaccinated in both 2015/16 and 2016/17 seasons as a reference, we computed the effectiveness of being vaccinated in 2015/16 season only, in 2016/17 season only and in both seasons.

Vaccine effectiveness against influenza A(H3N2) in 2016/17
==========================================================

We included 1,073 influenza A(H3N2) cases, nine A(H1N1)pdm09 cases, 13 cases of influenza B and 1,541 controls between week 47, 2016 and week 14, 2017. Due to the small number of cases, we were not able to measure IVE against influenza A(H1N1)pdm09 and B. We excluded these 22 records from all analyses.

The median age of A(H3N2) cases was 81 years (range: 65−102 years) while that of controls was 80 (range: 65−102 years). Ninety-four percent of cases and 95% of controls had at least one underlying condition (p = 0.14). Controls were more likely than cases to have underlying lung disease (44 vs 37%, p \< 0.05), rheumatologic disease (22 vs 15%, p \< 0.05) and cancer (24 vs 19%, p \< 0.05), to have been hospitalised in the past 12 months (44 vs 33%, p \< 0.05) and to be current smokers (26 vs 20%, p \< 0.05) ([Table 1](#t1){ref-type="table"}).

###### Characteristics of influenza A(H3N2) hospitalised cases (n = 1,073) and test-negative controls (n = 1,541), I-MOVE + study, Europe, influenza season 2016/17

  ---------------------------------------------------------------------------------------------------------------------
                                                Influenza A(H3N2) cases\   Controls (n = 1,541)                 
                                                (n = 1,073)                                                     
  --------------------------------------------- -------------------------- ---------------------- ------------- -------
  Median age in years (range)                   81 (65--102)               80 (65--102)                         

  **Characteristic**                            **n/N^a^**                 **%**                  **n/N^a^**    **%**

  Aged 65--69 years                             457/1,073                  42.6                   770/1,541     50.0

  Sex = male                                    516/1,072                  48.1                   815/1,535     53.1

  2016/17 seasonal influenza vaccination        556/1,073                  51.8                   894/1,541     58.0

  2015/16 seasonal influenza vaccination        578/1,054                  54.8                   896/1,525     58.8

  **Current and previous vaccination status**                                                                   

  2016/17 seasonal vaccine only                 46/1,054                   4.4                    99/1,525      6.5

  2015/16 seasonal vaccine only                 73/1,054                   6.9                    112/1,525     7.3

  2015/16 and 2016/17 seasonal vaccines         505/1,054                  47.9                   784/1,525     51.4

  **Type of 2016/17 vaccine**                                                                                   

  Not vaccinated                                517/1,007                  48.2                   647/1,421     42.0

  Inactivated subunit egg                       243/1,007                  22.6                   431/1,421     28.0

  Inactivated split virion egg                  229/1,007                  21.3                   321/1,421     20.8

  Adjuvanted                                    18/1,007                   1.7                    22/1,421      1.4

  **Underlying conditions**                                                                                     

  Diabetes mellitus                             325/1,072                  30.3                   473/1,540     30.7

  Heart disease                                 710/1,070                  66.4                   1,032/1,541   67.0

  Lung disease                                  392/1,069                  36.7                   672/1,534     43.8

  Cancer                                        201/1,069                  18.8                   369/1,533     24.1

  Renal disease                                 223/1,071                  20.8                   319/1,539     20.7

  Stroke                                        125/879                    14.2                   176/1,287     13.7

  Rheumatologic disease                         157/1,070                  14.7                   341/1,539     22.2

  Obesity^b^                                    124/1,062                  11.7                   154/1,527     10.1

  Any underlying condition                      996/1,063                  93.7                   1,456/1,531   95.1

  At least two underlying conditions            776/1,025                  75.7                   1,206/1,491   80.9

  Functional impairment                         399/1,066                  37.4                   588/1,529     38.5

  Hospitalisations in past 12 months            353/1,063                  33.2                   668/1,526     43.8

  Current smoker                                182/901                    20.2                   318/1,220     26.1

  **Potential for misclassification**                                                                           

  Antivirals received before swabbing           177/1,069                  16.0                   90/1,535      5.8

  Swabbing within 3 days of symptom onset       653/1,073                  58.7                   876/1,541     56.2

  **Study sites**                                                                                               

  Croatia                                       31/1,073                   2.9                    13/1,541      0.8

  Finland                                       20/1,073                   1.9                    50/1,541      3.2

  France                                        119/1,073                  11.1                   209/1,541     13.6

  Hungary                                       8/1,073                    0.7                    19/1,541      1.2

  Italy                                         73/1,073                   6.8                    136/1,541     8.8

  Lithuania                                     67/1,073                   6.2                    58/1,541      3.8

  Navarre, Spain                                242/1,073                  22.6                   290/1,541     18.8

  The Netherlands                               40/1,073                   3.7                    63/1,541      4.1

  Portugal                                      49/1,073                   4.6                    29/1,541      1.9

  Romania                                       90/1,073                   8.4                    103/1,541     6.7

  Spain^c^                                      334/1,073                  31.1                   571/1,541     37.1
  ---------------------------------------------------------------------------------------------------------------------

I MOVE+: Integrated Monitoring of Vaccines in Europe plus.

^a^ N represents the total number of cases or controls with available information.

^b^ Defined as body mass index ≥ 30 kg/m^2^.

^c^ Excluding Navarre.

The one-stage pooled adjusted IVE was 17% (95% confidence interval (CI): 1 to 31) overall; 25% (95% CI: 2 to 43) among patients aged 65--79 years and 10% (95 %CI: −15 to 30) among those aged 80 years and above. Among patients with specific underlying conditions, IVE ranged between 19% (95% CI: −1 to 35) among patients with heart disease and 35% (95% CI: 14 to 51) among patients with lung disease ([Table 2](#t2){ref-type="table"}).

###### Seasonal influenza vaccine effectiveness against influenza influenza A(H3N2) overall and stratified by patient characteristics, I-MOVE + study, Europe, influenza season 2016/17

  Population and patient characteristics     Vaccinated /cases   \%   Vaccinated /controls   \%   Adjusted IVE   95% CI
  ------------------------------------------ ------------------- ---- ---------------------- ---- -------------- -----------
  Aged 65 years and above - age/time^a^      556/1,073           52   894/1,541              58   17             1 to 31
  Aged 65 years and above - full model^a^    544/1,041           52   868/1,494              58   14             −3 to 29
  Aged 65--79 years - age/time^a^            175/457             38   382/770                50   25             2 to 43
  Aged 80 years and above - age/time^a^      381/616             62   512/771                66   13             −12 to 32
  **According to underlying diseases**                                                                           
  Diabetes mellitus                          183/320             57   295/468                63   22             −8 to 44
  Heart disease                              378/703             54   622/1,024              61   19             −1 to 35
  Lung disease                               209/386             54   440/668                66   35             14 to 51
  Cancer                                     105/198             53   227/362                63   21             −19 to 47
  At least two underlying chronic diseases   414/767             54   732/1,196              61   17             −2 to 33
  **According to previous vaccination**                                                                          
  Not vaccinated in 2015/16                  46/473              10   99/623                 16   39             −3 to 59
  Vaccinated in 2015/16                      502/572             88   776/887                87   −2             −44 to 28
  **Sensitivity analyses**                                                                                       
  Swabbed within 3 days                      502/872             58   333/629                53   8              −16 to 28
  No antivirals before swabbing              867/1,446           60   509/904                56   14             −3 to 29

I MOVE+: Integrated Monitoring of Vaccines in Europe plus.

^a^ Variables used for adjustment:

-age/time: adjusted for study site, age and onset date (modelled as a restricted cubic spline with 3 and 4 knots respectively);

-full model: adjusted for study site, onset date, age (modelled as a restricted cubic spline with 3 and 4 knots respectively), lung diseases, heart diseases, diabetes, obesity, renal diseases, cancer and hospitalisation in the past 12 months;

-other estimates were adjusted for study site, onset date, age (modelled as a restricted cubic spline with 3 and 4 knots respectively) and hospitalisation in the past 12 months.

The 2016/17 seasonal IVE was −2% (95% CI: −44 to 28) among patients who had received 2015/16 seasonal influenza vaccine and 39% (95 %CI: −3 to 59) among patients not vaccinated in 2015/16 ([Table 2](#t2){ref-type="table"}). Taking as a reference patients unvaccinated in 2015/16 and 2016/17, IVE for those vaccinated in 2015/16 only was 19% (95% CI: −15 to 42) and IVE when vaccinated both in 2015/16 and 2016/17 was 15% (95 %CI: −3 to 30) ([Table 3](#t3){ref-type="table"}).

###### Seasonal influenza vaccine effectiveness against influenza A(H3N2) by vaccine uptake in 2015/16, 2016/17 and in both seasons, I-MOVE + study, Europe, influenza season 2016/17

  Vaccine uptake in 2015/16 and 2016/17 influenza seasons   Cases   Controls   IVE         95% CI
  --------------------------------------------------------- ------- ---------- ----------- -----------
  Not vaccinated                                            427     524        Reference   
  2016/17 only                                              46      99         38          9 to 58
  2015/16 only                                              70      111        19          −15 to 42
  Vaccinated in both seasons                                502     776        15          −3 to 30

CI: confidence interval; I-MOVE+: Integrated Monitoring of Vaccines in Europe plus; IVE: influenza vaccine effectiveness.

^a^ Adjusted for study site, age and onset date (modelled as a restricted cubic spline with 3 and 4 knots, respectively).

The A(H3N2) vaccine components were A/Switzerland/2013 (3C.3a) in the 2015/16 seasonal vaccine and A/Hong Kong/2014 (3c.2a) in the 2016/17 seasonal vaccine.

Discussion
==========

In the 2016/17 influenza season, A(H3N2) viruses largely predominated. IVE against hospitalisation with influenza A(H3N2) virus infection among persons aged 65 years and above was low at 17%. The IVE point estimate was even lower (10%) among patients aged 80 years and above. IVE was similar among patients with heart disease, diabetes mellitus and cancer. The IVE point estimate was higher among patients with lung disease. While 95% CIs were largely overlapping, the 2016/17 IVE point estimate was lower (IVE: −2%) among patients vaccinated also in 2015/16 than among those unvaccinated in 2015/16 (IVE: 39%).

Low IVE against influenza A(H3N2) among persons aged 65 years and above has been previously observed in hospital settings \[[@r6]-[@r8]\]. A recent meta-analysis measured that the pooled IVE against hospitalisation with influenza A(H3N2) in seasons when circulating and vaccine strains were antigenically different was 14% (95% CI: −3 to 30) among persons aged 65 years and above \[[@r9]\]. It was 43% (95% CI: 33 to 53) in seasons when circulating and vaccine A(H3N2) strains were antigenically similar; 48% (95% CI: 37 to 59) against influenza A(H1N1)pdm09 and 38% (95% CI: 25 to 53) against influenza B \[[@r9]\].

Based on specimens received from week 40/2016 to week 5/2017, available antigenic data from the World Health Organization (WHO) European Region indicated that most circulating viruses that could be analysed were considered as antigenically similar to the 2016/17 vaccine component \[[@r10]\]. Consequently, European data supported the WHO recommendation to maintain the same vaccine component A/Hong Kong/4801/2014 (clade 3C.2a) for influenza A(H3N2) in the 2017/18 season vaccine for the northern hemisphere \[[@r11]\]. However, one third of viruses isolated during the above-mentioned period could not be assigned to an antigenic reporting category, reflecting technical challenges or antigenic changes in circulating viruses. Genetic data from Europe centralised at the ECDC suggested that circulating A(H3N2) viruses had undergone considerable genetic diversification during the above-mentioned period, with the emergence of subclusters within clade 3C.2a and subclade 3C.2a1 \[[@r10]\].

In September 2017, WHO updated the A(H3N2) component to A/Singapore/INFIMH-16-0019/2016 (subclade 3C.2a1) in the 2018 seasonal vaccine for the southern hemisphere \[[@r12]\]. The latest WHO update on 2 October 2017, reported that influenza A(H3N2) viruses were still predominating worldwide in September 2017. Further genetic information was not provided at this stage \[[@r13]\].

Our results taking patients unvaccinated in both 2015/16 and 2016/17 seasons as a reference suggested that influenza vaccination in 2015/16 and/or 2016/17 reduced the risk of influenza-associated hospitalisation among vaccinated patients. Our stratified results suggested that 2015/16 vaccination modified the 2016/17 IVE. Although too imprecise to be conclusive, our results could suggest that patients vaccinated in both seasons benefited from a residual protection from the 2015/16 vaccine, with no additional effect of the 2016/17 vaccine uptake.

Conclusion
==========

Our results suggest a low IVE against hospitalised influenza A(H3N2) among persons aged 65 years and above, particularly among patients aged 80 years and above. They also suggest a modifying effect of 2015/16 influenza vaccination on 2016/17 IVE. The A(H3N2) virus component included in the 2017/18 vaccine will remain the same as in the 2016/17 season. The latest WHO influenza surveillance report suggests that influenza A(H3N2) viruses were predominating worldwide in August 2017. Low IVE may be expected during the 2017/18 season in case of predominant circulation of A(H3N2) viruses. However, IVE against influenza A(H1N1)pdm09 and B are usually reported to be higher. Close monitoring of virological surveillance data will be required to prompt early promotion of complementary measures such as the use of antivirals or non-pharmaceutical interventions.
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